Navigation Links
New drugs to find the right target to fight Alzheimer's disease
Date:8/2/2013

The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects. At the same time, the scientists offer a molecular explanation for early-onset hereditary forms of Alzheimer's, which can strike as early as thirty years of age. The conclusions of their research, which has been published in the journal Nature Communications, are very encouraging regarding the future of therapeutic means that could keep Alzheimer's disease in check.

Alzheimer's disease is characterized by an aggregation of small biological molecules known as amyloid peptides. We all produce these molecules; they play an essential antioxidant role. But in people with Alzheimer's disease, these peptides aggregate in the brain into toxic plaques called "amyloid plaques" that destroy the surrounding neurons.

The process starts with a long protein, "APP", which is located across the neuron's membrane. This protein is cut into several pieces by an enzyme, much like a ribbon is cut by scissors. The initial cut generates a smaller intracellular protein that plays a useful role in the neuron. Another cut releases the rest of APP outside the cell this part is the amyloid peptide.

For reasons not yet well understood, APP protein can be cut in several different places, producing amyloid peptides that are of varying lengths. Only the longer forms of the amyloid peptide carry the risk of aggregating into plaques, and people with Alzheimer's disease produce an abnormally high number of these.

A favorite Alzheimer's target: gamma secretase

The two next-generation classes of compound that are currently in clinical trials target an enzyme that cuts APP, known as gamma secretase. Until now, our
'/>"/>

Contact: Patrick Fraering
patrick.fraering@epfl.ch
41-795-938-785
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Alternative target for breast cancer drugs
2. Toward broad-spectrum antiviral drugs for common cold and other infections
3. Gene variants may predict who will benefit from breast cancer prevention drugs
4. New screening technique paves the way for protein drugs from bacteria
5. Soda and illegal drugs cause similar damage to teeth
6. A new strategy required in the search for Alzheimers drugs?
7. Drugs found to both prevent and treat Alzheimers disease in mice
8. Renaissance in new drugs for rare diseases
9. Renaissance in new drugs for rare diseases: Report in worlds largest scientific socity magazine
10. How do anticancer drugs work?
11. Mapping of cancer cell fuel pumps paves the way for new drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical ... use solutions, headquartered in Springville, Utah , ... California corporation with locations in Santa ... Rica ). This acquisition will incorporate MedConx,s ... ATL Technology,s existing facility in Costa Rica ...
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... attack. Since 2006, more than a million have been killed. ... not been enough evidence to implicate the suspectuntil now. ... is the causal agent of White-nose Syndrome (WNS), the fungal ... by Justin Boyles, a post-doctoral research associate in ecology and ...
... WASHINGTON, D.C. OCT. 31, 2011 A highly ... born to obese and diabetic women have a higher ... metabolic health problems later in life, received the March ... in the field of maternal-fetal nutrition. , ...
... Now, it,s on to proteins, a much more daunting task. ... protein molecules in our bodies. Many of these hold keys ... by Northwestern University chemical biologist Neil Kelleher has developed a ... protein molecules quickly. Many have been skeptical that such an ...
Cached Biology News:UT scientist helps confirm link between fungus and bat epidemic 2March of Dimes honors researcher who linked maternal obesity to a baby's long-term health 2So many proteins, so much promise 2So many proteins, so much promise 3
(Date:7/29/2015)... BIRMINGHAM, Ala., July 29, 2015 /PRNewswire/ ... the nation,s largest providers of post-acute healthcare services, ... reported its results of operations for the second ... second quarter was characterized by strong volume growth ... our Adjusted EBITDA," said Jay Grinney, President and ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)... 2015  Therapath Neuropathology ( www.Therapath.com ), a ... VA and Military Medical centers both domestically and ... and Sweat Gland Nerve Fiber Density (SGNFD) for ... ). Demonstration of a reduction ... punch skin biopsy is a highly sensitive and ...
(Date:7/29/2015)... NJ (PRWEB) , ... July 29, 2015 , ... The ... approval of combination products , in particular, drug/device combinations. The current system received ... by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ...
Breaking Biology Technology:HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34HealthSouth Reports Results for Second Quarter 2015 35HealthSouth Reports Results for Second Quarter 2015 36
... improved IT infrastructure and enterprise plan for Wisconsin ... efficiency, according to presenters at the second annual ... the Monona Terrace. , ,Discussion focused on how ... increase access to broadband networks, educational services, and ...
... University of Wisconsin-Madison announced on Friday that it will be ... research. R. Timothy Mulcahy, a professor of pharmacology and associate ... become vice president of research at the University of Minnesota ... Martin Cadwallader said in a statement. He has been a ...
... recently saw the sudden death of another star. In this ... also not his birthplace. Unfortunately, few were around to sing ... last few weeks of the sudden death of biotech scientist ... in September of this year. An Argentine by birth, Frydman ...
Cached Biology Technology:Wisconsin introduces new state IT plan 2Wisconsin introduces new state IT plan 3Wisconsin introduces new state IT plan 4UW-Madison associate dean, active in stem cells, leaves 2An Argentine biotechman in Wisconsin 2An Argentine biotechman in Wisconsin 3An Argentine biotechman in Wisconsin 4
... Services include subcloning of gene in ... cells, isolation and plaque purification of ... virus stock for one clone, protein ... insect cell culture. Expected yield and ...
... Synthesis Service provides you with ... knockdown any gene. We offer ... pairs with terminal dT nucleotides), ... lengths of your choice. Each ...
EDTA, tetrasodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99-101% (as is).Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemicals, Ul...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Biology Products: